-
公开(公告)号：US20220001040A1
公开(公告)日：2022-01-06
申请号：US17483393
申请日：2021-09-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. MORIN , David DONNELLY , Dasa LIPOVSEK , Jochem GOKEMEIJER , Maria N. JURE-KUNKEL , David FABRIZIO , Martin C. WRIGHT , Douglas DISCHINO , Samuel J. BONACORSI, JR. , Ralph Adam SMITH , Virginie LAFONT , Daniel COHEN
Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.
-
公开(公告)号：US20190077844A1
公开(公告)日：2019-03-14
申请号：US15760449
申请日：2016-09-22
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Dasa LIPOVSEK , Joseph TOTH , Ginger C. RAKESTRAW , Irvith M. CARVAJAL , Stanley Richard KRYSTEK, JR. , Steven R. O'NEIL , Guodong CHEN , Richard Y. HUANG , Bryan C. BARNHART , John Thomas LOFFREDO , Christina TERRAGNI
CPC classification number: C07K14/78 , A61K38/00 , A61K47/60 , A61K47/64 , A61K47/6435 , G01N33/6872
Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.
-
公开(公告)号：US20170354718A1
公开(公告)日：2017-12-14
申请号：US15491271
申请日：2017-04-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon CLOAD , Linda ENGLE , Dasa LIPOVSEK , Malavi MADIREDDI , Ginger Chao RAKESTRAW , Joanna SWAIN , Wenjun ZHAO , Alexander T. KOZHICH , Martin J. CORBETT
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
公开(公告)号：US20170275342A1
公开(公告)日：2017-09-28
申请号：US15440730
申请日：2017-02-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Dasa LIPOVSEK , Richard W. WAGNER , Robert G. KUIMELIS
CPC classification number: C07K14/47 , C07K14/525 , C07K14/78 , C07K16/00 , C07K16/241 , C07K2317/22 , C07K2318/20 , C07K2319/00 , C07K2319/30 , C12N15/1037 , C12Q1/00 , C40B40/02
Abstract: Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands.
-
公开(公告)号：US20140107020A1
公开(公告)日：2014-04-17
申请号：US14025307
申请日：2013-09-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon CLOAD , Linda ENGLE , Dasa LIPOVSEK , Malavi MADIREDDI , Ginger Chao RAKESTRAW , Joanna SWAIN , Wenjun ZHAO
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
Patent Agency Ranking
公开(公告)号：US20240316161A1
公开(公告)日：2024-09-26
申请号：US18482248
申请日：2023-10-06
Applicant: Bristol-Myers Squibb Company
Inventor： Sharon CLOAD , Linda ENGLE , Dasa LIPOVSEK , Malavi MADIREDDI , Ginger Chao RAKESTRAW , Joanna SWAIN , Wenjun ZHAO , Hui WEI , Aaron P. YAMNIUK , Vidhyashankar RAMAMURTHY , Alexander T. KOZHICH , Martin J. CORBETT , Stanley Richard KRYSTEK, JR.
IPC: A61K38/39 , A61K38/00 , A61K38/17 , A61K45/06 , A61K47/60 , A61K47/64 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , G01N33/74
CPC classification number: A61K38/39 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , G01N33/74 , A61K38/00 , C07K2319/30 , C07K2319/31
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
公开(公告)号：US20220275535A1
公开(公告)日：2022-09-01
申请号：US17673625
申请日：2022-02-16
Applicant: Bristol-Myers Squibb Company
Inventor： Jonathan DAVIS , Dasa LIPOVSEK , Ray CAMPHAUSEN
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
公开(公告)号：US20200283505A1
公开(公告)日：2020-09-10
申请号：US16748085
申请日：2020-01-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stanley Richard KRYSTEK, JR. , Tracy S. MITCHELL , Michael L. GOSSELIN , Dasa LIPOVSEK , Juhi JUNEJA
IPC: C07K14/78 , C07K14/765 , C12N15/85
Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
-
公开(公告)号：US20180258158A1
公开(公告)日：2018-09-13
申请号：US15760413
申请日：2016-09-22
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stanley Richard KRYSTEK, Jr. , Tracy S. MITCHELL , Michael L. GOSSELIN , Dasa LIPOVSEK , Juhi JUNEJA
IPC: C07K14/78 , C07K14/765 , C12N15/85
Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
-
公开(公告)号：US20170183393A1
公开(公告)日：2017-06-29
申请号：US15127183
申请日：2015-03-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Dasa LIPOVSEK
IPC: C07K14/78
Abstract: Provided herein are proteins comprising a fibronectin based scaffold (FBS) domain, e.g., 10Fn3 molecules, that bind specifically to a target, and wherein the FBS domain is linked at its C-terminus to a region consisting of PmXn, wherein P is proline, X is any amino acid and wherein n is 0 or an integer that is at least 1 and m is an integer that is at least 1, and wherein the PmXn moiety provides an enhanced property to the FBS domain, e.g., enhanced stability, relative to the protein that is not linked to the PmXn moiety.
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.036 seconds)
